{
  "id": "resp_06d3dfb23850a20100693c929f2b048190a35a7e08025e6ee2",
  "object": "response",
  "created_at": 1765577375,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_06d3dfb23850a20100693c929fb54081909ebed14c0f8bed26",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92a3c3ec8190ba0f316754a708b6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT CDK12/13 inhibitor TNBC"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92a547c8819084bf4722b33890bd",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92a7b1ec8190b961e5a7d742fee6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT SR-4835"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92a9e9488190a9baea5ad1645a47",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92ab5b1c8190a094bb1735d9888b",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "dinaciclib epirubicin EudraCT"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92ad42c881909cbfdd5b3fccda4f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92af99348190973e96be220ae0d7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu dinaciclib breast cancer EudraCT"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92b30ce88190b52bc6f9d2658507",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92bbd5e48190b6c10f24c4b5d7fd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "SR-4835 patent WO"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92bddcb48190aac23cae478c4d01",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92c512788190997075e8e52071d8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92c6f20c8190984abf0fe49846d2",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_06d3dfb23850a20100693c92c797e8819080300113350ffc55",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu \"CDK12\""
      }
    },
    {
      "id": "rs_06d3dfb23850a20100693c92ca1f7c819083905c98ae156d8f",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_06d3dfb23850a20100693c92db9ba081909741f20d7b8c00f3",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 364,
              "start_index": 276,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 568,
              "start_index": 480,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 934,
              "start_index": 846,
              "title": "CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32941949/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 1092,
              "start_index": 1004,
              "title": "CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32941949/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 1515,
              "start_index": 1427,
              "title": "Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37695916/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 1672,
              "start_index": 1584,
              "title": "Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37695916/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 1992,
              "start_index": 1904,
              "title": "Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27571479/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 2154,
              "start_index": 2066,
              "title": "Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27571479/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 2565,
              "start_index": 2477,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 2761,
              "start_index": 2673,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3014,
              "start_index": 2907,
              "title": "SR-4835 Datasheet",
              "url": "https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3154,
              "start_index": 3047,
              "title": "SR-4835 Datasheet",
              "url": "https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3335,
              "start_index": 3228,
              "title": "SR-4835 Datasheet",
              "url": "https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3550,
              "start_index": 3472,
              "title": "THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem",
              "url": "https://www.axonmedchem.com/3402-thz531?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3656,
              "start_index": 3578,
              "title": "THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem",
              "url": "https://www.axonmedchem.com/3402-thz531?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3828,
              "start_index": 3750,
              "title": "THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem",
              "url": "https://www.axonmedchem.com/3402-thz531?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 4019,
              "start_index": 3940,
              "title": "Probe THZ531 | Chemical Probes Portal",
              "url": "https://www.chemicalprobes.org/thz531?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 4142,
              "start_index": 4063,
              "title": "Probe THZ531 | Chemical Probes Portal",
              "url": "https://www.chemicalprobes.org/thz531?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 4267,
              "start_index": 4188,
              "title": "Probe THZ531 | Chemical Probes Portal",
              "url": "https://www.chemicalprobes.org/thz531?utm_source=openai"
            }
          ],
          "logprobs": [],
          "text": "- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (PubMed)\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/31668947/`\n  - Quotes:\n    - “SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai))\n    - “Targeting chromatin modifiers or catalytic effectors of transcription is an emerging anti-cancer strategy.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai))\n\n- CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer (PubMed)\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/32941949/`\n  - Quotes:\n    - “combined treatment of SR-4835, a CDK12/13 specific inhibitor, with PD-1 blockade” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32941949/?utm_source=openai))\n    - “SR-4835-treated tumor cells exhibited characteristics of ICD” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32941949/?utm_source=openai))\n\n- Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13 (PubMed)\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/37695916/`\n  - Quotes:\n    - “inhibition of cyclin-dependent kinases 12 and 13 (CDK12/13) dramatically sensitizes diverse models of TNBC to EGFR blockade.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37695916/?utm_source=openai))\n    - “Sensitization to EGFR inhibition with THZ531 in TNBC cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37695916/?utm_source=openai))\n\n- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors (PubMed)\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/27571479/`\n  - Quotes:\n    - “a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27571479/?utm_source=openai))\n    - “IC_{50} values for CDK12 and 13 were 158 and 69 nM, respectively” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27571479/?utm_source=openai))\n\n- Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor (PubMed)\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/34864331/`\n  - Quotes:\n    - “we have synthesized a potent PROTAC degrader PP-C8 based on the noncovalent dual inhibitors of CDK12/13” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai))\n    - “synergistic antiproliferative effects with PARP inhibitor in triple-negative breast cancer (TNBC).” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai))\n\n- SR-4835 Datasheet (Selleckchem)\n  - URL: `https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html`\n  - Quotes:\n    - “# SR-4835” ([selleckchem.com](https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai))\n    - “CAS No.  | 2387704-62-1” ([selleckchem.com](https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai))\n    - “SR-4835 is a selective, potent dual inhibitor of CDK12 and CDK13” ([selleckchem.com](https://www.selleckchem.com/datasheet/sr-4835-S889402-DataSheet.html?utm_source=openai))\n\n- THZ531 | CDK12/13 inhibitor | Axon 3402 (Axon Medchem)\n  - URL: `https://www.axonmedchem.com/3402-thz531`\n  - Quotes:\n    - “THZ531” ([axonmedchem.com](https://www.axonmedchem.com/3402-thz531?utm_source=openai))\n    - “CAS:  1702809-17-3” ([axonmedchem.com](https://www.axonmedchem.com/3402-thz531?utm_source=openai))\n    - “THZ531 is a first-in-class, potent, selective, covalent inhibitor of CDK12 and CDK13” ([axonmedchem.com](https://www.axonmedchem.com/3402-thz531?utm_source=openai))\n\n- THZ531 (Chemical Probes Portal)\n  - URL: `https://www.chemicalprobes.org/thz531`\n  - Quotes:\n    - “THZ531” ([chemicalprobes.org](https://www.chemicalprobes.org/thz531?utm_source=openai))\n    - “Covalent Inhibitor of CDK12, CDK13” ([chemicalprobes.org](https://www.chemicalprobes.org/thz531?utm_source=openai))\n    - “DOI Reference: 10.1038/nchembio.2166” ([chemicalprobes.org](https://www.chemicalprobes.org/thz531?utm_source=openai))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 30079,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 4734,
    "output_tokens_details": {
      "reasoning_tokens": 3651
    },
    "total_tokens": 34813
  },
  "user": null,
  "metadata": {}
}